ArticleFrontiers in cellular and infection microbiology2025
Immunogenicity of subunit vaccine of E2 protein against atypical porcine pestivirus in pigs.
Article in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: An atypical porcine pestivirus (APPV) causes congenital tremor (CT) type A-II in piglets and has caused considerable financial losses to the pig industry worldwide. This study aimed to develop an effective vaccine candidate against APPV. Methods: We constructed a prokaryotic expression system for the APPV E2 protein in Escherichia coli. The immunogenicity of the APPV E2 subunit vaccine, formulated with three different adjuvants (ISA 201VG, IMS 1313VG, and Gel 02), was evaluated in piglets. Assessment was based on E2-specific antibody levels measured by an in-house enzyme-linked immunosorbent assay (ELISA) and protection against an APPV challenge. Successful expression of the E2 protein was confirmed by western blot analysis. Results: The E2 protein was successfully expressed, and an E2-ELISA detection method was established. Vaccinated piglets mounted virus-specific IgG responses. The E2 protein emulsified with ISA 201VG and Gel 02 adjuvants induced significantly higher antibody levels than the formulation with IMS 1313VG adjuvant. The vaccine with ISA 201VG adjuvant yielded the highest antibody levels and provided protection against APPV infection. Histopathological examination confirmed normal organ morphology in vaccinated pigs, whereas the control group displayed significant pathological alterations. Discussion: The results demonstrate that the Escherichia coli-expressed E2 protein elicits an immune response in pigs. The E2 subunit vaccine is a potential candidate for preventing APPV infection, and ISA 201VG and Gel 02 adjuvants are suitable candidate adjuvants for vaccine preparation. This study provides a foundation for further APPV vaccine research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.